The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 19, 2021

Filed:

Oct. 09, 2017
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Michael T. Rudd, Collegeville, PA (US);

Zhaoyang Meng, Ambler, PA (US);

Jenny Wai, Harleysville, PA (US);

David Jonathan Bennett, Winchester, MA (US);

Edward J. Brnardic, Lansdale, PA (US);

Nigel J. Liverton, Harleysville, PA (US);

Shawn J. Stachel, Perkasie, PA (US);

Yongxin Han, Needham, MA (US);

Paul Tempest, Taipei, TW;

Jiuxiang Zhu, Shanghai, CN;

Xuewang Xu, Shanghai, CN;

Bin Zhu, Shanghai, CN;

Chuanman Huang, Shanghai, CN;

Inventors:

Michael T. Rudd, Collegeville, PA (US);

Zhaoyang Meng, Ambler, PA (US);

Jenny Wai, Harleysville, PA (US);

David Jonathan Bennett, Winchester, MA (US);

Edward J. Brnardic, Lansdale, PA (US);

Nigel J. Liverton, Harleysville, PA (US);

Shawn J. Stachel, Perkasie, PA (US);

Yongxin Han, Needham, MA (US);

Paul Tempest, Taipei, TW;

Jiuxiang Zhu, Shanghai, CN;

Xuewang Xu, Shanghai, CN;

Bin Zhu, Shanghai, CN;

Chuanman Huang, Shanghai, CN;

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 221/20 (2006.01); C07D 211/16 (2006.01); C07D 211/96 (2006.01);
U.S. Cl.
CPC ...
C07D 221/20 (2013.01); C07D 211/16 (2013.01); C07D 211/96 (2013.01);
Abstract

In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R, R, R, L, R, L, Q, and Rare as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-β receptor (LXRβ) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.


Find Patent Forward Citations

Loading…